---
layout: post
title: "招银国际：维持开拓药业(09939.HK)买入评级 目标价由34.37港元上调至48.78港元"
date: 2022-04-07 12:42:34 +0800
categories: jinshishuju
tags: 金十数据新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/116.09939" data-code="09939|116|5" data-code2="09939|116|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.09939&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 09939_0" data-code="K 09939|116|5" data-code2="K 09939|116|3|" style="border:#d1d1d1 1px solid;" width="577" height="275" /></a></p><!-- EM_StockImg_End --><p>招银国际：维持开拓药业(09939.HK)买入评级，目标价由34.37港元上调至48.78港元，看好其新冠口服药普克鲁胺治疗潜力。<br /></p><p class="em_media">（文章来源：金十数据）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204072334894824>

[返回金十数据新闻](//finews.withounder.com/category/jinshishuju.html)｜[返回首页](//finews.withounder.com/)